Diabetes Care, Vol 21, Issue 2 261-264, Copyright © 1998 by American Diabetes Association

ARTICLES

Biological variation of glycated hemoglobin. Implications for diabetes screening and monitoring

ES Kilpatrick, PW Maylor and BG Keevil
Department of Chemical Pathology, South Manchester Hospitals University NHS Trust, U.K.

OBJECTIVE: To assess the inherent potential of glycated hemoglobin as a screening test for type 2 diabetes by determining the biological variation in nondiabetic subjects. RESEARCH DESIGN AND METHODS: HbA1c values were measured by high-performance liquid chromatography (HPLC) in 12 nondiabetic subjects (7 men and 5 women; median age, 40 years [range, 21-55 years]) on 10 fortnightly occasions. The nondiabetic index of individuality (IOI) for HbA1c (i.e., the square root of the ratio of intra- to interindividual variance) was determined. Any test with an IOI of 1.4 has the most potential in disease screening, while one of 0.6 will be of little value. RESULTS: The analytical variance contributed to 9% of the total test variance, intraindividual variance, 6%; and interindividual variance, 85%. The IOI was, therefore, only 0.27. Thus, nondiabetic HbA1c values vary markedly between subjects, while values in the same individual change little with time. As such, to lie outside the assay reference range, the HbA1c values of some nondiabetic subjects must exceed 12 SD from their usual mean value, while in others a change of only 2 SD would be sufficient. CONCLUSIONS: This fundamental characteristic of HbA1c means that even if analytical methods improve, glycated hemoglobin measurements will always be of limited value when screening for type 2 diabetes. If similar interindividual differences also exist in diabetic subjects, then patients with the same glycemic control may vary by at least 1-2%, which has implications in setting glycated hemoglobin targets.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. M. Cohen A1C: Does One Size Fit All? Diabetes Care, October 1, 2007; 30(10): 2756 - 2758. [Full Text] [PDF]

				L. Herranz, L. Saez-de-Ibarra, C. Grande, and L. F. Pallardo Non-Glycemic-Dependent Reduction of Late Pregnancy A1C Levels in Women With Type 1 Diabetes Diabetes Care, June 1, 2007; 30(6): 1579 - 1580. [Full Text] [PDF]

				W S A Smellie, J Forth, D Bareford, P Twomey, M J Galloway, E C M Logan, S R S Smart, T M Reynolds, and C Waine Best practice in primary care pathology: review 3. J. Clin. Pathol., August 1, 2006; 59(8): 781 - 789. [Abstract] [Full Text] [PDF]

				R. J. McCarter, J. M. Hempe, and S. A. Chalew Mean Blood Glucose and Biological Variation Have Greater Influence on HbA1c Levels Than Glucose Instability: An analysis of data from the Diabetes Control and Complications Trial Diabetes Care, February 1, 2006; 29(2): 352 - 355. [Abstract] [Full Text] [PDF]

				L. Engel and H. Lindner Impact of Using a Pedometer on Time Spent Walking in Older Adults With Type 2 Diabetes The Diabetes Educator, January 1, 2006; 32(1): 98 - 107. [Abstract] [Full Text] [PDF]

				S. A. Chalew, J. M. Hempe, and R. J. McCarter Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to Genuth, Lachin, and Nathan Diabetes Care, January 1, 2005; 28(1): 234 - 235. [Full Text] [PDF]

				M. D. Breyer, E. Bottinger, F. C. Brosius III, T. M. Coffman, R. C. Harris, C. W. Heilig, K. Sharma, and for the AMDCC Mouse Models of Diabetic Nephropathy J. Am. Soc. Nephrol., January 1, 2005; 16(1): 27 - 45. [Abstract] [Full Text] [PDF]

				D. E. Goldstein, R. R. Little, R. A. Lorenz, J. I. Malone, D. Nathan, C. M. Peterson, and D. B. Sacks Tests of Glycemia in Diabetes Diabetes Care, July 1, 2004; 27(7): 1761 - 1773. [Full Text] [PDF]

				R. J. McCarter, J. M. Hempe, R. Gomez, and S. A. Chalew Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes Diabetes Care, June 1, 2004; 27(6): 1259 - 1264. [Abstract] [Full Text] [PDF]

				E S Kilpatrick HbA1c measurement J. Clin. Pathol., April 1, 2004; 57(4): 344 - 345. [Full Text] [PDF]

				J. Trape, J. M. Botargues, F. Porta, C. Ricos, J. M. Badal, R. Salinas, M. Sala, and A. Roca Reference Change Value for {alpha}-Fetoprotein and Its Application in Early Detection of Hepatocellular Carcinoma in Patients with Hepatic Disease Clin. Chem., July 1, 2003; 49(7): 1209 - 1211. [Full Text] [PDF]

				M. Okada, S. Nomura, Y. Ikoma, E. Yamamoto, T. Ito, T. Mitsui, K. Tamakoshi, and S. Mizutani Effects of Postmenopausal Hormone Replacement Therapy on HbA1c Levels Diabetes Care, April 1, 2003; 26(4): 1088 - 1092. [Abstract] [Full Text] [PDF]

				D. R. Jesudason, K. Dunstan, D. Leong, and G. A. Wittert Macrovascular Risk and Diagnostic Criteria for Type 2 Diabetes: Implications for the use of FPG and HbA1c for cost-effective screening Diabetes Care, February 1, 2003; 26(2): 485 - 490. [Abstract] [Full Text] [PDF]

				R G. Barr, D. M. Nathan, J. B. Meigs, and D. E. Singer Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus Ann Intern Med, August 20, 2002; 137(4): 263 - 272. [Abstract] [Full Text] [PDF]

				C. Rohlfing, H.-M. Wiedmeyer, R. Little, V. L. Grotz, A. Tennill, J. England, R. Madsen, and D. Goldstein Biological Variation of Glycohemoglobin Clin. Chem., July 1, 2002; 48(7): 1116 - 1118. [Full Text] [PDF]

				C. L. Rohlfing, H.-M. Wiedmeyer, R. R. Little, J. D. England, A. Tennill, and D. E. Goldstein Defining the Relationship Between Plasma Glucose and HbA1c: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial Diabetes Care, February 1, 2002; 25(2): 275 - 278. [Abstract] [Full Text] [PDF]

				H. Snieder, P. A. Sawtell, L. Ross, J. Walker, T. D. Spector, and R. D. G. Leslie HbA1c Levels Are Genetically Determined Even in Type 1 Diabetes: Evidence From Healthy and Diabetic Twins Diabetes, December 1, 2001; 50(12): 2858 - 2863. [Abstract] [Full Text] [PDF]

				R. C. Perry, R. R. Shankar, N. Fineberg, J. McGill, and A. D. Baron HbA1c Measurement Improves the Detection of Type 2 Diabetes in High-Risk Individuals With Nondiagnostic Levels of Fasting Plasma Glucose: The Early Diabetes Intervention Program (EDIP) Diabetes Care, March 1, 2001; 24(3): 465 - 471. [Abstract] [Full Text]

				E. S Kilpatrick Glycated haemoglobin in the year 2000 J. Clin. Pathol., May 1, 2000; 53(5): 335 - 339. [Full Text] [PDF]